Azitra Q3 2026 net loss widens 7% to $3 million
AZTR•Azitra’s third-quarter 2026 net loss widened 7% year over year to $3 million. Cash and cash equivalents totaled $3.8 million at September 30, and the company expects topline data from ATR-04 in the fourth quarter.
1. Quarterly results and trials
Azitra reported a third-quarter net loss of $3 million, up 7% year over year, while research and development expenses rose 8% to $1.3 million. Cash and cash equivalents totaled $3.8 million at September 30. ATR-04 completed Cohort 1 of its Phase 1/2 trial, with topline data expected in the fourth quarter of 2026; eligibility expanded to patients with KRAS and MEK inhibitor-associated rash. Initial results from the planned first-in-human cosmetic study of ATR-COSF are expected by year-end 2026.
